Join to view full profile
11100 Euclid AveCleveland, OH 44106
Phone+1 216-844-3951
Fax+1 216-844-5759
Dr. Bajor is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013- University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2010
Case Western Reserve University School of MedicineClass of 2007
Certifications & Licensure
OH State Medical License 2016 - 2027
PA State Medical License 2007 - 2016
American Board of Internal Medicine Medical Oncology
Clinical Trials
- CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer Start of enrollment: 2016 Sep 12
Publications & Presentations
PubMed
- TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.Christos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, Henry G Withers, David L Bajor
International Journal of Cancer. 2026-06-15 - 3 citationsTucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis.John H Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng
Nature Communications. 2026-01-12 - Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment.Veronica Mears, Nikolas Naleid, Omkar Pawar, Jennifer Eva Selfridge, Madison Conces
JCO Oncology Practice. 2025-09-01
Press Mentions
Combining Two Cancer Drugs Can Be Effective in Treating Specific Type of Colorectal Cancer, Study ShowsMay 2nd, 2022
Adoptive Cell TherapyDecember 12th, 2018
Immunotherapy Combo Appears Safe, Shrinks Metastatic Melanoma TumorsJune 2nd, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
